Skip to main content
LNTHLantheus Holdings, Inc.Hold6.2·$100.95-0.02%

Lantheus Holdings (LNTH) Q2 2026 earnings — TrendMatrix coverage

BEAT+18.9% vs estimateEPS $1.55 vs $1.30 estVerdict HoldSell

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$1.55
Estimate
$1.30
Surprise
+18.9%
Revenue (period 2026-06-30)
$388.2M
Score at report (before → after)
6.66.5/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

Lantheus Holdings (LNTH) beat the $1.30 estimate with diluted EPS of $1.55 — a large 18.9% upside surprise. TrendMatrix's engine moved from Hold (6.6/10) to Sell at 6.5/10 after the report — the engine's score fell despite the beat.

Current read · as of 2026-09-04

Where TrendMatrix's rating stands now

TrendMatrix currently rates LNTH Hold at 6.2/10.

3 of the last 4 quarters beat the estimate; this quarter's +18.9% surprise compares with a +20.2% four-quarter average. Next scheduled report: 2026-11-05.

What supports the rating

  • V7 flight-to-quality bonus: +0.5 (Q=8.5 in RISK_OFF)
  • Sector modifier (Healthcare): +0.5

What argues against it

  • Concentration risk — Supplier: sole suppliers (synthesis boxes, lipid blend)
  • Analyst target reached - limited upside remaining
  • Earnings estimates trending DOWN

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$100.95
Price target
$116.09
Stop
$99.86
Upside to target
+15.0%

The stock trades at 24.1× trailing but 16.0× forward earnings — consensus estimates already build in a substantial earnings recovery.

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare context

LNTH at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Drug Manufacturers - Specialty & Generic
Market cap
$6.59B
P/E (fwd)
16.0
P/E (ttm)
24.1
52-week range
$49.67$111.86
Off 52-week high
9.8%
RSI (14)
50
Volume vs avg
0.49×
Score today
6.2/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks LNTH Earnings Q2 2026 earnings